[Midazolam versus dexmedetomidine for sedation for upper gastrointestinal endoscopy]

Area of Science:

• Gastroenterology
• Anesthesiology
• Clinical Pharmacology

Background:

• Upper gastrointestinal endoscopy (UGI) is a common diagnostic procedure.
• While generally safe, UGI carries risks of cardiopulmonary complications, necessitating effective sedation.
• Optimizing sedation is crucial for patient safety and procedural success.

Purpose of the Study:

• To evaluate and compare the safety and efficacy of dexmedetomidine versus midazolam for sedation during UGI procedures.
• To assess key patient outcomes including sedation levels, recovery time, and satisfaction.

Main Methods:

• A randomized controlled, double-blind clinical trial was conducted.
• Patients undergoing UGI were randomized to receive sedation with either dexmedetomidine or midazolam.
• Outcomes measured included sedation depth (Ramsay scale), recovery time, patient satisfaction, and adverse events.

Main Results:

• Forty patients were included, with 20 in each sedation group.
• Demographic and physical status (age, sex, BMI, ASA) were similar between groups.
• Dexmedetomidine resulted in significantly shorter recovery times (7.1 min vs. 15.8 min) and higher patient satisfaction (9.9 vs. 9.0) compared to midazolam.
• Sedation levels and adverse event proportions were comparable between the two agents.

Conclusions:

• Both dexmedetomidine and midazolam are effective and suitable sedative agents for UGI endoscopy.
• Dexmedetomidine demonstrates advantages in terms of reduced recovery time and enhanced patient satisfaction.
• These findings suggest dexmedetomidine as a potentially preferred option for UGI sedation.